Symptoms of children and adolescents infected with SARS-CoV-2 variants alpha, delta or omicron

1

2 Hansjörg Schulze¹, Wibke Bayer^{*}

³ ¹ Institute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany

- 4 * Correspondence:
- 5 Wibke Bayer
- 6 wibke.bayer@uk-essen.de

7 Keywords: SARS-CoV-2, symptoms, children, adolescents, mild disease

- 8
- 9

10 Abstract

- 11 Symptoms experienced by children and adolescents with SARS-CoV-2 infections in the alpha, delta
- 12 and omicron variant dominated phases were investigated using an online survey, and the frequencies
- 13 of reported symptoms and changes over time were analyzed. The most prevalent symptoms were
- 14 fever above 38 °C, tiredness, headache, runny or blocked nose, sneezing and dry cough. Lethargy and
- 15 nausea were reported significantly more frequently in the omicron variant dominated phase than in
- 16 the earlier phases of the pandemic. Compared to symptoms reported by adults, fever and
- 17 gastrointestinal symptoms were reported more frequently for children, especially in the omicron
- 18 variant dominated phase, whereas the frequency of loss of smell and loss of taste was significantly
- 19 lower in children than in adults.
- 20

21 Introduction

- 22 The SARS-CoV-2 pandemic started in late 2019 in Wuhan, China, where the first cases and human-
- 23 to-human transmission were reported [1], and the virus spread quickly all over the world. By August
- 24 2023, more than 769 million people have been infected according to data from the World Health
- 25 Organization [2], which is very likely an underestimate since testing for SARS-CoV-2 has been

26 reduced significantly since spring 2023 as SARS-CoV-2 has no longer been considered a public

health emergency [3].

- 28 SARS-CoV-2 can induce severe disease in adults as well as in children, but mild disease is most
- 29 common in both children and adults. The rate of asymptomatic infections is generally hard to
- 30 determine and reported numbers vary widely; different meta-analyses calculated asymptomatic
- 31 infection rates in children in the earlier phases of the pandemic of 19.3% [4], 13.1% [5] or 46.7% [6].
- 32 In the symptomatic infections, cough, nausea, vomiting and diarrhea have been reported as the most
- 33 frequent symptoms of children during the early, SARS-CoV-2 D614G dominated phase of the
- 34 pandemic [5]. For later, variant-dominated phases, increases in the frequency of fever, cough and
- 35 upper respiratory tract symptoms have been described [7].
- 36 We have previously reported on a detailed study of self-reported symptoms by SARS-CoV-2 infected

37 adults during four different phases of the pandemic, where we determined the frequency of more than

38 40 different symptoms and analyzed changes in the variant-dominated phases [8]. Our new data now

39 provide detailed insight into symptoms experienced by SARS-CoV-2 infected children in phases of

- 40 the pandemic that were dominated by different SARS-CoV-2 variants, and we present a side-by-side
- 41 comparison with symptom frequencies reported by adults.
- 42

43 Methods

44 Ethics Approval

45 The study was approved by the local Ethics Committee of the Medical Faculty of the University

46 Duisburg-Essen (approval number 20-9233-BO). The study was carried out in accordance with the

47 ethical guidelines and regulations. The study participants and a parent or another legal representative

48 gave their informed consent to their voluntary participation in the study and to the subsequent use of

49 the data for publication.

50 Data collection

51 Data were obtained using an online questionnaire based on the LimeSurvey software which was

52 hosted on the servers of the University Duisburg-Essen. Participants for the study were recruited via

53 the public health offices of the administrative district of Soest (North Rhine-Westphalia, Germany)

- 54 and of the administrative district Hochsauerlandkreis (North Rhine-Westphalia, Germany) when they
- 55 received their confirmation of a positive SARS-CoV-2 PCR test result. The data presented in this
- 56 manuscript were collected between January 23rd 2021 and March 22nd 2022. During this time, official
- 57 SARS-CoV-2 antigen testing was accessible in Germany when a SARS-CoV-2 infection was
- suspected with or without respiratory symptoms or prior contact. Semi-weekly self-testing or pool-
- 59 testing was introduced from April 2021 for children visiting a kindergarten or school. An individual
- 60 PCR test was mandatory after a positive official or at-home antigen test or pool PCR test. Official
- 61 PCR test results and resulting quarantines were managed by the public health offices.

62 Data analysis

- 63 Data were analyzed using R (version 3.6.3) and RStudio software and fmsb, plyr, splyr, tidyverse,
- 64 reshape2, stats, ggplot2 and viridis packages. Only data from individuals who had completed the
- 65 survey were included in the analysis.
- 66 For graphical representation, a heatmap of the data was created with ggplot2 after sorting the
- 67 responses by the date of survey completion and by the age of the respondents. The category "fever >
- 68 38.0 °C" was added after calculation from the survey responses using the tidyverse package.
- 69 The test for statistically significant differences in symptom frequencies between SARS-CoV-2
- 70 infected children in the alpha, delta and omicron variant dominated phases and in symptom
- 71 frequencies between children from the current survey and adults from our previous symptom study
- 72 [8] was performed using Fisher's exact test using the function fisher.test of the R stats package. The
- test for statistically significant differences in the age distribution of the respondents from the alpha,
- 74 delta and omicron variant dominated phases was performed by One Way analysis of variance (One
- 75 Way ANOVA) using the function aov() of the R stats package.
- 76

77 **Results**

- An online based survey was performed to gather information on the prevalence of different
- 79 symptoms in children and adolescents after infection with SARS-CoV-2. Participants were recruited
- 80 by their local health office. In total, 101 responses were obtained from or for children and adolescents
- 81 aged between 0 years and 18 years (Table 1). The study started in January 2021 during the SARS-
- 82 CoV-2 alpha variant dominated phase (in Germany: February 2021 June 2021), and data were

83 collected over a period of more than a year, thus also covering the delta variant (July 2021 – January 84 2022) and omicron variant dominated phases (from January 2022; [9]). The major characteristics of 85 the participants from the three phases are comparable, with a majority of respondents between 7 and 86 12 years old. The subjective assessment of the severity of the infection, ranging from asymptomatic 87 over mild (e.g.: "symptoms without feeling ill") and moderately ill (e.g.: "feeling ill and lying on 88 sofa") to very ill (e.g.: "feeling ill and having to stay in bed") resulted in a majority (overall 50.5%, 89 alpha: 58.3%, delta: 43.2%, omicron: 55.6%) of respondents answering with "moderately ill". Only a 90 minority of 5.9% overall (alpha: 8.3%, delta 11.4%, omicron 0%) reported an asymptomatic 91 infection. None of the respondents reported a hospitalization or the necessity of intensive care

92 treatment due to the SARS-CoV-2 infection (0%).

93 The symptoms reported by the survey respondents are shown in Figure 1A as a heatmap and as 94 bargraphs in Figure 2. The most frequently reported symptoms included general symptoms such as 95 fever, tiredness and headaches, and more specific respiratory symptoms such as a runny or blocked 96 nose and dry cough. The comparison of the symptoms reported during the three different phases of 97 the pandemic (Figure 2B), i.e. the alpha, delta, and omicron variant dominated phases, revealed only 98 minor differences in symptom frequencies with the exception of blocked nose, which dropped from 99 83.3% in the alpha variant dominated phase to 47.7% and 42.2.% during the delta and omicron 100 variant dominated phases, respectively, and changes in the frequency of lethargy (alpha: 25%, delta: 101 22.7%, omicron: 53.3%), loss of smell (alpha: 8.3%, delta: 18.2%, omicron: 4.4%) and nausea 102 (alpha: 16.7%, delta: 9.1%, omicron: 33.3%). Importantly, differences observed in the three phases 103 do not correlate to a difference in the age distribution of the respondents (Figure 1B, no significant 104 differences, One Way ANOVA).

105 We have reported before on the results of a similar symptom survey where we gathered information 106 about symptoms experienced by adults infected with SARS-CoV-2 [8]. Performing a side-by-side 107 comparison, we found that symptom frequencies during all three variant dominated phases differed 108 between adults and children, with most general symptoms such as lethargy (alpha: adults 60.5%, 109 children 25%; delta: adults 50.2%, children 22.7%; (omicron: adults 46.5%, children 53.3%)), 110 headache (alpha: adults 68.3%, children 58.3%; delta: adults 67.4%, children 47.7%; omicron: adults 111 65.7%, children 60%), muscle pains (alpha: adults 31%, children 8.3%; delta: adults 28.4%, children 112 11.4%; omicron: adults 30.4%, children 20%) and sweating (alpha: adults 21.9%, children 8.3%;

delta: adults 28.4%, children 11.4%; omicron: adults 21%, children 6.7%) reported at significantly

114 lower frequency for SARS-CoV-2 infected children compared to SARS-CoV-2 infected adults 115 (Figure 3). While the frequencies of the hallmark symptoms of SARS-CoV-2 infection, loss of smell 116 and taste, were also significantly lower in children in all three variant dominated phases (loss of 117 smell/taste, alpha: adults 48.2%/42%, children 8.3%/8.3%; delta: adults 60.6%/54.6%, children 118 18.2%/18.2%; omicron: adults 25%/23.8%, children 4.4%/8.9%), other symptom frequencies were 119 elevated in children compared to adults, notably the frequency of fever higher than 38 °C (alpha: 120 adults 19.4%, children 41.7%; delta: adults 17.9%, children 47.7%; omicron: adults 16.6%, children 121 44.4%) and gastrointestinal symptoms such as nausea (alpha: adults 19.4%, children 16.7%; delta: 122 adults 12.9%, children 9.1%;) omicron: adults 11.7%, children 33.3%), vomiting (alpha: adults 2.7%, 123 children 16.7%; delta: adults 1.8%, children 9.1%; omicron: adults 1.2%, children 26.7%), abdominal 124 pain (alpha: adults 10.3%, children 25%; delta: adults 8.5%, children 15.9%; omicron: adults 8.9%,

- 125 children 28.9%) and abdominal cramps (alpha: adults 6.5%, children 0%; delta: adults 5%, children
- 126 4.5%;) omicron: adults 3.5%, children 11.1%).
- 127

128 **Discussion**

In this report, we provide a detailed analysis of the symptoms experienced by SARS-CoV-2 infected children, and show that the symptoms reported most often and at rates of more than 40% were fever above 38 °C, tiredness, headache, runny nose, blocked nose, sneezing and dry cough. It is interesting to note that in comparison to symptom frequencies reported by adults, we observed many minor differences, and a significantly higher frequency of fever and a strikingly lower frequency of loss of smell and taste was observed in children compared to adults.

135 It has been reported before that a very high percentage of SARS-CoV-2 infected children

136 experienced fever, and rates in other reports are often even higher than the frequency reported by us

137 [4; 5; 7]. We found that the frequency of fever above 38 °C was significantly higher in children

- 138 compared to adults, which may be explained by the finding that the expression levels of type I
- 139 interferons are higher in children than in adults [10; 11; 12; 13; 14].
- 140 The loss of smell and/or loss of taste has been considered a hallmark symptom of SARS-CoV-2
- 141 infection since the beginning of the pandemic [15], and was shown by us [8] and others to have
- 142 decreased in frequency in adults infected with SARS-CoV-2 since the spread of the SARS-CoV-2
- 143 omicron variant [16] from a frequency around 60% to below 20%. The frequency in children

however was much lower in all three phases of the pandemic that we analyzed here, which is in
agreement with findings by others; it was shown in a meta-analysis that the frequencies in individual
studies varied markedly and that children of more than ten years of age were more likely to
experience loss of smell or taste [17].

148 There are some limitations to our study, most importantly that the total number of respondents was 149 low, and children below the age of 6 and between 13 and 18 years old are less represented than the 150 age group of 7 to 12 years old. We were therefore not able to correlate symptom frequencies with age 151 groups, and would also like to point out the relatively low number of respondents with regard to the 152 comparison of symptom frequencies for the three different SARS-CoV-2 variants. Furthermore, the 153 symptoms of SARS-CoV-2 infected children were either self-reported or reported by a parent and 154 can be subjective, and the presence of some symptoms such as headache, joint pain or muscle pain 155 can be difficult or impossible to assess or to distinguish in very young children. As is always the case 156 with self-report questionnaires, there is a certain response bias in that it is more likely that infected 157 individuals with symptoms, or in this case the parents of the young individuals, take part in the study 158 than asymptomatic individuals. Even though a few individuals reported no symptoms, this rate 159 should not be construed as the rate of asymptomatic infection. In many cases, the questionnaires were 160 completed within a week after the positive PCR test, but in general the study has to be considered 161 partly retrospective, which may have resulted in a less clear picture than a daily questionnaire. With 162 regard to the attribution of the infections to a certain SARS-CoV-2 dominated phase, it has to be 163 pointed out that infection with a certain variant was not confirmed and that the attribution was 164 performed solely on the date of questionnaire completion. While the alpha, delta and omicron 165 variants quickly replaced the respective preceding variants [9], there were short times of overlap 166 when both variants were present, which slightly weakens the allocation of responses to the variants. 167 Finally, we did not obtain information in this study about the duration of symptoms, and cannot 168 assess how long individual symptoms persisted.

Overall, our study provides additional insight into the symptoms experienced by SARS-CoV-2
 infected children and adolescents and contributes to understanding this infection in the young.

171

172 **References**

173 [1] P.f.M.E. Disease, Undiagnosed Pneumonia - China (Hubei): Request for Information, 2019.

174 [2] G. World Health Organization, WHO COVID-19 Dashboard., Available online: 175 https://covid19.who.int/, accessed: 2023-08-11. 176 [3] G. World Health Organization, World Health Organization Situations: Coronavirus disease 177 (COVID-19) pandemic, Available online: 178 https://www.who.int/europe/emergencies/situations/covid-19, accessed: 2023-08-11. 179 [4] A. Hoang, K. Chorath, A. Moreira, M. Evans, F. Burmeister-Morton, F. Burmeister, R. Naqvi, M. 180 Petershack, and A. Moreira, COVID-19 in 7780 pediatric patients: A systematic review. 181 eClinicalMedicine 24 (2020). 182 [5] O. Irfan, F. Muttalib, K. Tang, L. Jiang, Z.S. Lassi, and Z. Bhutta, Clinical characteristics, 183 treatment and outcomes of paediatric COVID-19: a systematic review and meta-analysis. 184 Archives of Disease in Childhood 106 (2021) 440-448. [6] P. Sah, M.C. Fitzpatrick, C.F. Zimmer, E. Abdollahi, L. Juden-Kelly, S.M. Moghadas, B.H. 185 186 Singer, and A.P. Galvani, Asymptomatic SARS-CoV-2 infection: A systematic review and 187 meta-analysis. Proceedings of the National Academy of Sciences 118 (2021). 188 [7] M.W. Sumner, J. Xie, R. Zemek, K. Winston, G. Freire, B. Burstein, A. Kam, J. Emsley, J. 189 Gravel, R. Porter, V. Sabhaney, A. Mater, M.I. Salvadori, S. Berthelot, D. Beer, N. Poonai, A. 190 Moffatt, B. Wright, S.B. Freedman, S. Ali, M. Newton, W. Alqurashi, M. Lorenzo, T. 191 Crawford, and B. Emerton, Comparison of Symptoms Associated With SARS-CoV-2 192 Variants Among Children in Canada. JAMA Network Open 6 (2023). 193 [8] H. Schulze, and W. Bayer, Changes in Symptoms Experienced by SARS-CoV-2-Infected 194 Individuals – From the First Wave to the Omicron Variant. Frontiers in Virology 2 (2022). 195 [9] E.B. Hodcroft, CoVariants: SARS-CoV-2 Mutations and Variants of Interest. (2021). 196 [10] C.A. Pierce, S. Sy, B. Galen, D.Y. Goldstein, E. Orner, M.J. Keller, K.C. Herold, and B.C. 197 Herold, Natural mucosal barriers and COVID-19 in children. JCI Insight 6 (2021). 198 [11] J. Loske, J. Röhmel, S. Lukassen, S. Stricker, V.G. Magalhães, J. Liebig, R.L. Chua, L. 199 Thürmann, M. Messingschlager, A. Seegebarth, B. Timmermann, S. Klages, M. Ralser, B. 200 Sawitzki, L.E. Sander, V.M. Corman, C. Conrad, S. Laudi, M. Binder, S. Trump, R. Eils, 201 M.A. Mall, and I. Lehmann, Pre-activated antiviral innate immunity in the upper airways 202 controls early SARS-CoV-2 infection in children. Nature Biotechnology 40 (2021) 319-324. 203 [12] M. Yoshida, K.B. Worlock, N. Huang, R.G.H. Lindeboom, C.R. Butler, N. Kumasaka, C. 204 Dominguez Conde, L. Mamanova, L. Bolt, L. Richardson, K. Polanski, E. Madissoon, J.L. 205 Barnes, J. Allen-Hyttinen, E. Kilich, B.C. Jones, A. de Wilton, A. Wilbrey-Clark, W. 206 Sungnak, J.P. Pett, J. Weller, E. Prigmore, H. Yung, P. Mehta, A. Saleh, A. Saigal, V. Chu, 207 J.M. Cohen, C. Cane, A. Iordanidou, S. Shibuya, A.-K. Reuschl, I.T. Herczeg, A.C. Argento, 208 R.G. Wunderink, S.B. Smith, T.A. Poor, C.A. Gao, J.E. Dematte, G.R.S. Budinger, H.K. 209 Donnelly, N.S. Markov, Z. Lu, G. Reynolds, M. Haniffa, G.S. Bowyer, M. Coates, M.R. 210 Clatworthy, F.J. Calero-Nieto, B. Göttgens, C. O'Callaghan, N.J. Sebire, C. Jolly, P. De 211 Coppi, C.M. Smith, A.V. Misharin, S.M. Janes, S.A. Teichmann, M.Z. Nikolić, and K.B. 212 Meyer, Local and systemic responses to SARS-CoV-2 infection in children and adults. Nature 213 602 (2021) 321-327. 214 [13] K. Sacco, R. Castagnoli, S. Vakkilainen, C. Liu, O.M. Delmonte, C. Oguz, I.M. Kaplan, S. 215 Alehashemi, P.D. Burbelo, F. Bhuyan, A.A. de Jesus, K. Dobbs, L.B. Rosen, A. Cheng, E. 216 Shaw, M.S. Vakkilainen, F. Pala, J. Lack, Y. Zhang, D.L. Fink, V. Oikonomou, A.L. Snow, 217 C.L. Dalgard, J. Chen, B.A. Sellers, G.A. Montealegre Sanchez, K. Barron, E. Rey-Jurado, C.

218	Vial, M.C. Poli, A. Licari, D. Montagna, G.L. Marseglia, F. Licciardi, U. Ramenghi, V.
219	Discepolo, A. Lo Vecchio, A. Guarino, E.M. Eisenstein, L. Imberti, A. Sottini, A. Biondi, S.
220	Mató, D. Gerstbacher, M. Truong, M.A. Stack, M. Magliocco, M. Bosticardo, T. Kawai, J.J.
221	Danielson, T. Hulett, M. Askenazi, S. Hu, J. Barnett, X. Cheng, K. Kaladi, V. Kuram, J.
222	Mackey, N.M. Bansal, A.J. Martins, B. Palterer, H. Matthews, U. Mudunuri, M. Nambiar,
223	A.J. Oler, A. Rastegar, S. Samuel, C. Shyu, V. Waingankar, S. Weber, S. Xirasagar, Y.
224	Espinosa, C. Astudillo, C. Piñera, R. González, M. De Filippo, M. Votto, L. Montagna, J.I.
225	Cohen, H.C. Su, D.B. Kuhns, M.S. Lionakis, T.M. Snyder, S.M. Holland, R. Goldbach-
226	Mansky, J.S. Tsang, and L.D. Notarangelo, Immunopathological signatures in multisystem
227	inflammatory syndrome in children and pediatric COVID-19. Nature Medicine 28 (2022)
228	1050-1062.

- [14] A. Pierangeli, M. Gentile, G. Oliveto, F. Frasca, L. Sorrentino, L. Matera, R. Nenna, A. Viscido,
 M. Fracella, L. Petrarca, G. D'Ettorre, G. Ceccarelli, F. Midulla, G. Antonelli, and C.
 Scagnolari, Comparison by Age of the Local Interferon Response to SARS-CoV-2 Suggests a
 Role for IFN-ε and -ω. Frontiers in Immunology 13 (2022).
- [15] H. Streeck, B. Schulte, B. Kuemmerer, E. Richter, T. Hoeller, C. Fuhrmann, E. Bartok, R.
 Dolscheid, M. Berger, L. Wessendorf, M. Eschbach-Bludau, A. Kellings, A. Schwaiger, M.
 Coenen, P. Hoffmann, M. Noethen, A.-M. Eis-Huebinger, M. Exner, R. Schmithausen, M.
 Schmid, and G. Hartmann, Infection fatality rate of SARS-CoV-2 infection in a German
 community with a super-spreading event. Nat Commun 11 (2020) 5829.
- [16] C.S. von Bartheld, and L. Wang, Prevalence of Olfactory Dysfunction with the Omicron Variant
 of SARS-CoV-2: A Systematic Review and Meta-Analysis. Cells 12 (2023).
- [17] Q. Yan, D. Qiu, X. Liu, X. Guo, and Y. Hu, Prevalence of Smell or Taste Dysfunction Among
 Children With COVID-19 Infection: A Systematic Review and Meta-Analysis. Frontiers in
 Pediatrics 9 (2021).
- 243
- 244 Tables
- 245 Table 1 Characteristics of the study population

subgroup number	all respondents 101	alpha 12	delta 44	omicron 45
age (years)				
0-6	27 (26.7%)	3 (25%)	14 (31.8%)	10 (22.2%)
7-12	61 (60.4%)	6 (50%)	26 (59.1%)	29 (64.4%)
13-18	13 (12.9%)	3 (25%)	4 (9.1%)	6 (13.3%)
gender				
female	54 (53.5%)	4 (33.3%)	26 (59.1%)	24 (53.3%)
male	47 (46.5%)	8 (66.6%)	18 (40.9%)	21 (46.7%)
smoking				
active	0 (0%)	0 (0%)	0 (0%)	0 (0%)
passive	6 (5.9%)	1 (8.3%)	2 (4.5%)	3 (6.7%)

hayfever ¹	4 (3.9%)	0 (0%)	1 (2.3%)	3 (6.7%)
severity asymptomatic mild ² moderately ill ³ very ill ⁴ hospitalization intensive care treatment	6 (5.9%) 34 (33.7%) 51 (50.5%) 10 (9.9%) 0 (0%) 0 (0%)	1 (8.3%) 3 (25%) 7 (58.3%) 1 (8.3%) 0 (0%) 0 (0%)	5 (11.4%) 19 (43.2%) 19 (43.2%) 1 (2.3%) 0 (0%) 0 (0%)	0 (0%) 12 (26.7%) 25 (55.6%) 8 (17.8%) 0 (0%) 0 (0%)

¹ hayfever relevant at the time of infection

247 ² e.g. "I did not feel ill but had a runny nose"

³e.g. "I felt ill and lay on the sofa"

⁴ e.g. "I felt very ill and had to stay in bed"

250

251 Figure Legends

252 Figure 1 Heatmap of symptoms of SARS-CoV-2-infected children and adolescents. (A)

253 Symptoms of SARS-CoV-2 infected children and adolescents as reported during the alpha (top),

delta (delta) and omicron dominated phases (bottom) of the SARS-CoV-2 pandemic, responses were

sorted by variant phase and age of the participant. "feverish/not feverish": subjective judgement,

body temperature was not measured. (B) The graph shows the age of the respondents from the alpha,

257 delta and omicron variant dominated phases of the SARS-CoV-2 pandemic. Each dot indicates an

individual, n.s. = not significant (P > 0.05, One Way ANOVA).

259 Figure 2 Frequency of symptoms stratified by SARS-CoV-2 variant. Barplots indicate the

260 frequency of the indicated symptoms reported by all respondents (A) or by the respondents infected

261 during the alpha, delta or omicron dominated phases (B). * indicates statistically significant

262 differences compared to the frequency during the alpha variant dominated phase, # indicates

statistically significant differences compared to the frequency during the delta variant dominated

264 phase (P < 0.05, Fisher's exact test).

265 Figure 3 Comparison of symptom frequencies reported by adults and children. The frequencies

of symptoms reported by adults have been reported before in a previous publication [8] and are

shown by grey bars. The frequencies of children are shown as purple bars. Significant differences

between frequencies reported by adults and children are indicated by * (P < 0.05, Fisher's exact test).

- 269 n.a. = not available: data were not acquired in the previous study.
- 270

271 Conflict of Interest

272 The authors declare that the research was conducted in the absence of any commercial or financial

273 relationships that could be construed as a potential conflict of interest.

274 Ethics Statement

- 275 The studies involving human participants were reviewed and approved by Ethik-Kommission der
- 276 Medizinischen Fakultät der Universität Duisburg-Essen Robert-Koch-Str. 9-11 45147 Essen
- 277 Germany. The patients/participants provided their informed consent to participate in this study.

278 Author Contributions

- HS recruited participants and contributed to writing the manuscript. WB conceived of the study,
- created the online survey, analyzed data and wrote the manuscript. All authors contributed to the article and approved the submitted version
- article and approved the submitted version.
- 282

283 Acknowledgments


We would like to thank all participants for taking part in our survey.


285

286 Data Availability Statement


The raw data supporting the conclusions of this article will be made available by the authors, without


undue reservation.





В





omicron

4.6

